March 18, 2008 – Luminous Medical, Inc. announced that it has completed a $23.5 million round of Series B financing. Adams Street Partners led the investment, joined by new investors RiverVest Venture Partners, and Finistere Ventures. Existing investors De Novo Ventures and Latterell Venture Partners also participated in the round.
The company is developing an automated blood glucose monitor for in-hospital use with critically ill patients. Establishing tight glucose control in these patients has been shown to improve outcomes including highly significant reductions in complications, length of stay and mortality. The Luminous Medical monitor will simplify the implementation of tight glucose control by providing frequent glucose measurements automatically... [PDF] Luminous Medical's Press Release -
Blog Archive
-
▼
2008
(233)
-
▼
April
(49)
- Echo : Prelude SkinPrep System, the Next-Generatio...
- Rigel's R788 : Preclinical Activity in Type 1 Diab...
- Pelikan and Lilly : Diabetes Education Alliance
- Smiths Medical to Promote and Distribute Abbott’s ...
- Medtronic : FDA Clearance of New OneTouch Ultralin...
- Metabasis Therapeutics : Extension of Its Collabor...
- Hadasit : Successful Phase I Study Results of a Ne...
- Innocoll : Phase 2 Clinical Trial to Investigate C...
- Pacira Pharmaceuticals and Amylin Pharmaceuticals ...
- Tolerx : Advancing Novel Type 1 Diabetes Agent int...
- Biovitrum : unique neuropathic pain compound is ve...
- SciGen and Generex : Distribution Agreement for Or...
- MetaCure : NewYork-Presbyterian/Weill Cornell Is F...
- GlaxoSmithKline to acquire Sirtris Pharmaceuticals...
- Medicure : Presentation of Phase II Matched Result...
- Daiichi Sankyo : Welchol Added to the ACE/AACE "Ro...
- AtheroGenics : Encouraging Interim Results From Ph...
- Pacific Biometrics : Research Contracts as Part of...
- AGI Therapeutics : key findings of clinical PK stu...
- Living Cell Technologies : Proprietary Nanobiocaps...
- Karo Bio : Positive Results in First Clinical Stud...
- Elixir Pharmaceuticals : National Diabetes Advisor...
- BioChemics & Beth Israel Deaconess Medical Center ...
- DiaKine : Lisofylline Reduces Obesity-Related Infl...
- PerkinElmer : New Innovations to Strengthen Drug D...
- Exelgen : Two New Major Drug Discovery Collaborat...
- Entelos : U.S. Patent for its Diabetes Model
- Kamada : AAT proved efficient in treating Type-1 ...
- Home Test Kits from BioIQ Help Consumers Detect Di...
- DiaKine Therapeutics & Kinexum Metabolics : Combin...
- 12-Month Data from Endeavor IV Show Strong Clinica...
- ArthroCareSports Medicine : to Tackle Diabetic Fo...
- WellDoc Communications : Diabetes Management Progr...
- Elixir Pharmaceuticals : enrollment in its final p...
- Pfizer Statement on Exubera Labeling Update in the US
- Diabetech Launches GlucoMON-RT Real-Time Monitorin...
- Luminous Medical : Automated Blood Glucose Monitor...
- Alimera Sciences and pSivida : DSMB again support...
- Metabolex : Phase 1 clinical trial of MBX-2982, Po...
- Takeda : ACTOS® (pioglitazone HCl) Prevented Progr...
- Cardium and Tissue Repair Company's Excellarate : ...
- Smiths Medical MD : voluntary recall of specific s...
- Owen Mumford Ltd : to discontinue Unilet GP and U...
- CV Therapeutics : New Data Shows Ranexa Increases ...
- Senesco : Preclinical Pancreatic Islet Data to be ...
- Aegera : Phase 1 Clinical Trial of AEG33773 - a Sm...
- Oculus Innovative Sciences : Chinese SFDA Regulato...
- BioMimetic Therapeutics Addresses FDA Communicatio...
- Novo Nordisk : FDA Approves NovoLog for Use in In...
-
▼
April
(49)
Wednesday, April 9, 2008
Luminous Medical : Automated Blood Glucose Monitor For Critical Care Use
Libellés :
Blood Glucose Monitoring,
Luminous Medical